Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Judy W.M. Cheng"'
Publikováno v:
Annals of Pharmacotherapy. 55:252-260
Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicat
Publikováno v:
Journal of Cardiovascular Pharmacology
Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (
Publikováno v:
Journal of Cardiovascular Pharmacology
Current guidelines recommend the consideration of positive inotropes in patients with acute decompensated heart failure (ADHF) who have low cardiac index and evidence of systemic hypoperfusion or congestion. However, there is no evidence detailing th
Autor:
Judy W.M. Cheng
Publikováno v:
Integrated Pharmacy Research & Practice
Pharmacists play an important role within a multidisciplinary health care team in the care of patients with heart failure (HF). It has been evaluated and documented that pharmacists providing medication reconciliation especially during transition of
Publikováno v:
Current Medical Research and Opinion. 33:985-992
This article reviews evidence of the benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008.Peer-reviewed articles were identified from MEDLINE and Current Content database
Autor:
Lina Matta, Lynne W. Stevenson, Joanne R. Weintraub, Elaine L. Shea, Judy W.M. Cheng, Mandeep R. Mehra, Kristina Navarro-Velez, Enrique Seoane-Vazquez, Ahmed Aldemerdash, Leo F. Buckley, D.S. Medina, Irene M. Cooper, Akshay S. Desai
Publikováno v:
The American Journal of Cardiology. 118:1350-1355
Innovative treatment strategies for decompensated heart failure (HF) are required to achieve cost savings and improvements in outcomes. We developed a decision analytic model from a hospital perspective to compare 2 strategies for the treatment of de
Publikováno v:
Clinical Cardiology. 40:46-52
A growing number of patients with an indication for stroke prevention in atrial fibrillation have kidney-, age-, or weight-related alterations in pharmacokinetics that affect dosing of direct oral anticoagulants. Because these patients were excluded
Publikováno v:
Postgraduate Medical Journal. 94:601-602
Allergic cutaneous reactions in patients on warfarin are rare and reported at an incidence of less than 0.1% in the literature.1 Nevertheless, various types of warfarin-induced cutaneous reactions have been reported, including vesicular, maculopapula
Autor:
Lina Matta, Akshay S. Desai, Lynne W. Stevenson, Craig A. Stevens, Judy W.M. Cheng, Jillian Dempsey, Danielle Carter
Publikováno v:
Journal of pharmacy practice. 30(3)
Background: The Ambulatory Cardiac Triage, Intervention, and Education (ACTIVE) infusion unit is an outpatient center that aims to provide heart failure (HF) patients with comprehensive multidisciplinary interventions. Objective: To describe the pati
Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes
Autor:
Judy W.M. Cheng
Publikováno v:
Clinical Therapeutics. 34:1209-1220
The clinical benefits of dual antiplatelet treatment (aspirin + clopidogrel) in the management of acute coronary syndromes (ACS) are well established. However, clopidogrel is a prodrug that requires hepatic activation. Concerns regarding its delayed